News and updates — Page 10 of 15 — German Market Access

Disease management programmes in Germany – IQWiG says it’s time for an update

Hi again, welcome to the series in quality assurance initiatives, starting with disease management programmes in Germany. This post will cover: Next

Welcome to the last post in the HTA series, focusing on the changes to HTA and early benefit assessments in Germany in

Welcome! In this post, I am going through the steps on how the G-BA chooses the appropriate comparative therapy (ACT). I conclude

This week, we are having a brief look at two brief reports on PROs recently published by the IQWiG. We’ll cover: As

Welcome, this week’s post on the G-BA’s views on endpoints is the second article in the benefit assessments series. You’ll learn about:

This is the first article in a series about maybe the most important topic influencing market access in Germany: HTAs or early

Hi! Welcome to the last article in the 3-part series on reimbursement. This time, I’m sharing some facts about private health insurance

Hello again, and welcome to the second post in the 3-part series on reimbursement. Last week, we focused on the reimbursement of

Welcome to the start of our 3-part series on reimbursement, starting with reimbursement of drugs in Germany. Today, you will learn about:

Hi, welcome back to the latest article. In the last few weeks, we have learned about how drugs are priced in Germany,